English | Russian | Kazakh
ONCOLOGY, NUCLEAR MEDICINE AND TRANSPLANTOLOGY
Case Report
Apr 23, 2026 24 13

Malignant Transformation of Hepatocellular Adenoma: Case Report

Murat Jakipov 1,
Xeniya Andreyeva 1 * ,
Sayazhan Nogaibayeva 1,
Aslan Karimov 1,
Bairam Kochiyev 1,
Islam Sherullayev 1,
Alisher Sarsenbayev 1,
Islambek Berikbayev 1,
Iskandar Afizov 1,
Zukhra Orazbek 1,
Zhandos Burkitbayev 2
1 Department of Radiology, National Research Oncology Center, Astana, Kazakhstan2 Chairman of the Board of the National Research Oncology Center, Astana, Kazakhstan* Corresponding Author
Oncology, Nuclear Medicine and Transplantology, 2(2), 2026, onmt017, https://doi.org/10.63946/onmt/18466
Publication date: Apr 23, 2026
Full Text (PDF)

ABSTRACT

Hepatocellular adenomas (HCA) are rare benign liver tumors associated with metabolic risk factors and carry a risk of malignant transformation. We present a case of a 50-year-old woman with a liver lesion initially diagnosed as a hepatocellular adenoma that showed progressive growth on follow-up imaging. Contrast-enhanced MRI (Magnetic Resonance Imaging) and CT (Computed Tomography) showed enlargement of the lesion in segments S6–S7. Initial biopsy findings were consistent with hepatocellular adenoma. Because of continued tumor growth, right liver resection was performed. Histopathological examination revealed foci of well-differentiated hepatocellular carcinoma arising within a dysplastic adenoma with areas of necrosis. This case highlights the diagnostic challenges in distinguishing hepatocellular adenoma from early hepatocellular carcinoma, particularly in patients with metabolic risk factors and progressive tumor enlargement. It emphasizes the importance of careful imaging surveillance and timely surgical management.

KEYWORDS

Hepatobiliary Tumors Hepatocellular Adenoma Hepatocellular Carcinoma Liver Pathology

CITATION (Vancouver)

Jakipov M, Andreyeva X, Nogaibayeva S, Karimov A, Kochiyev B, Sherullayev I, et al. Malignant Transformation of Hepatocellular Adenoma: Case Report. Oncology, Nuclear Medicine and Transplantology. 2026;2(2):onmt017. https://doi.org/10.63946/onmt/18466
APA
Jakipov, M., Andreyeva, X., Nogaibayeva, S., Karimov, A., Kochiyev, B., Sherullayev, I., Sarsenbayev, A., Berikbayev, I., Afizov, I., Orazbek, Z., & Burkitbayev, Z. (2026). Malignant Transformation of Hepatocellular Adenoma: Case Report. Oncology, Nuclear Medicine and Transplantology, 2(2), onmt017. https://doi.org/10.63946/onmt/18466
Harvard
Jakipov, M., Andreyeva, X., Nogaibayeva, S., Karimov, A., Kochiyev, B., Sherullayev, I., . . . Burkitbayev, Z. (2026). Malignant Transformation of Hepatocellular Adenoma: Case Report. Oncology, Nuclear Medicine and Transplantology, 2(2), onmt017. https://doi.org/10.63946/onmt/18466
AMA
Jakipov M, Andreyeva X, Nogaibayeva S, et al. Malignant Transformation of Hepatocellular Adenoma: Case Report. Oncology, Nuclear Medicine and Transplantology. 2026;2(2), onmt017. https://doi.org/10.63946/onmt/18466
Chicago
Jakipov, Murat, Xeniya Andreyeva, Sayazhan Nogaibayeva, Aslan Karimov, Bairam Kochiyev, Islam Sherullayev, Alisher Sarsenbayev, Islambek Berikbayev, Iskandar Afizov, Zukhra Orazbek, and Zhandos Burkitbayev. "Malignant Transformation of Hepatocellular Adenoma: Case Report". Oncology, Nuclear Medicine and Transplantology 2026 2 no. 2 (2026): onmt017. https://doi.org/10.63946/onmt/18466
MLA
Jakipov, Murat et al. "Malignant Transformation of Hepatocellular Adenoma: Case Report". Oncology, Nuclear Medicine and Transplantology, vol. 2, no. 2, 2026, onmt017. https://doi.org/10.63946/onmt/18466

REFERENCES

  1. Thevathasan T, Colbatzky T, Schmelzle M, Pratschke J, Krenzien F. Risk factors for malignant transformation of hepatocellular adenoma to hepatocellular carcinoma: protocol for systematic review and meta-analysis. BMJ Open. 2021 Aug 10;11(8):e045733. doi: 10.1136/bmjopen-2020-045733
  2. Rooks JB, Ory HW, Ishak KG, Strauss LT, Greenspan JR, Hill AP, Tyler CW Jr. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA. 1979;242:644–648. (No DOI available)
  3. Klompenhouwer AJ, de Man RA, Dioguardi Burgio M, Vilgrain V, Zucman-Rossi J, Ijzermans JNM. New insights in the management of Hepatocellular Adenoma. Liver Int. 2020 Jul;40(7):1529-1537. doi: 10.1111/liv.14547
  4. Cherqui D, Mathieu D, Zafrani ES, Dhumeaux D. [Focal nodular hyperplasia and hepatocellular adenoma in women. Current data]. Gastroenterol Clin Biol. 1997;21:929–935. (No DOI available)
  5. Farges O, Ferreira N, Dokmak S, et al. Changing trends in malignant transformation of hepatocellular adenoma. Gut. 2011;60:85–89. doi: 10.1136/gut.2010.222109
  6. Poetter-Lang S, Ba-Ssalamah A, Bastati N, Ba-Ssalamah SA, Hodge JC, Brancatelli G, Paradis V, Vilgrain V. Hepatocellular adenoma update: diagnosis, molecular classification, and clinical course. Br J Radiol. 2024 Nov;97(1163):1740–1754. doi: 10.1093/bjr/tqae180
  7. Frenette C, Mendiratta-Lala M, Salgia R, Wong RJ, Sauer BG, Pillai A. ACG Clinical Guideline: Focal Liver Lesions. Am J Gastroenterol. 2024 Jul;119(7):1235-1271. doi: 10.14309/ajg.0000000000002857
  8. Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Subtype classification of hepatocellular adenoma. Dig Surg. 2010;27(1):39-45. doi: 10.1159/000268406
  9. Myers L, Ahn J. Focal Nodular Hyperplasia and Hepatic Adenoma: Evaluation and Management. Clin Liver Dis. 2020 Aug;24(3):389-403. doi: 10.1016/j.cld.2020.04.013

LICENSE

Creative Commons License
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.